Literature DB >> 17565741

Identification of tumorigenic retinal stem-like cells in human solid retinoblastomas.

Xiufeng Zhong1, Yongping Li, Fuhua Peng, Bing Huang, Jianxian Lin, Wenxin Zhang, Jianliang Zheng, Ruzhang Jiang, Ge Song, Jian Ge.   

Abstract

Retinoblastoma (RB) is the most common malignant tumor of the retina in human children. Although it has been hypothesized for a long time that RB derives from multipotent retinal stem cells (RSCs) or retinoblasts, the direct evidence that the presence of tumorigenic RSCs in RB tumors is still lacking. Some studies indicate that malignant tumors contain tumor stem cells similar to their normal tissue stem cell counterparts. With in vitro culture and differentiation method we demonstrate that tumorigenic retinal stem-like cells (RSLCs) indeed exist in RB lesions and that RB tumor-derived cultures encompass undifferentiated cells capable of extensive proliferation as clonal nonadherent neurospheres and can differentiate into different retinal cells in vitro. Interestingly, cultured cells expressed retinal development related genes including nestin, CD133, pax6, chx10 and Rx, and overexpressed Bmi-1, a gene required for self-renewal and proliferation of stem cells. Significantly, when these cultured cells were intraocularly transplanted into SCID mice, they gave rise to new tumors with histomorphological features and immunophenotypes similar to their parental primary RBs. The results show that RBs contain tumorigenic RSLCs that contribute to tumorigenesis. This study provides a new insight to investigate the histogenesis of RBs and establishes a model for other RB research. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17565741     DOI: 10.1002/ijc.22880

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  26 in total

1.  In vitro characterization of CD133lo cancer stem cells in Retinoblastoma Y79 cell line.

Authors:  Rohini M Nair; Murali Ms Balla; Imran Khan; Ravi Kiran Reddy Kalathur; Paturu Kondaiah; Geeta K Vemuganti
Journal:  BMC Cancer       Date:  2017-11-21       Impact factor: 4.430

2.  Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells.

Authors:  Dimitrios Iliopoulos; Marianne Lindahl-Allen; Christos Polytarchou; Heather A Hirsch; Philip N Tsichlis; Kevin Struhl
Journal:  Mol Cell       Date:  2010-09-10       Impact factor: 17.970

3.  Coexpression of normally incompatible developmental pathways in retinoblastoma genesis.

Authors:  Justina McEvoy; Jacqueline Flores-Otero; Jiakun Zhang; Katie Nemeth; Rachel Brennan; Cori Bradley; Fred Krafcik; Carlos Rodriguez-Galindo; Matthew Wilson; Shunbin Xiong; Guillermina Lozano; Julien Sage; Ligia Fu; Lotfi Louhibi; Jeff Trimarchi; Amar Pani; Richard Smeyne; Dianna Johnson; Michael A Dyer
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

Review 4.  New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence.

Authors:  M Mimeault; S K Batra
Journal:  Histol Histopathol       Date:  2010-08       Impact factor: 2.303

5.  An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state.

Authors:  Christos Polytarchou; Dimitrios Iliopoulos; Kevin Struhl
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

6.  Differential expression of stem cell markers and vascular endothelial growth factor in human retinoblastoma tissue.

Authors:  Martha Kim; Jeong Hun Kim; Jin Hyoung Kim; Dong Hun Kim; Young Suk Yu
Journal:  Korean J Ophthalmol       Date:  2010-02-05

Review 7.  Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.

Authors:  M Mimeault; S K Batra
Journal:  Panminerva Med       Date:  2008-03       Impact factor: 5.197

8.  PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene.

Authors:  Joseph B Mascarenhas; Kacey P Young; Erica L Littlejohn; Brian K Yoo; Ravi Salgia; Deborah Lang
Journal:  J Biol Chem       Date:  2009-08-03       Impact factor: 5.157

9.  In human retinoblastoma Y79 cells okadaic acid-parthenolide co-treatment induces synergistic apoptotic effects, with PTEN as a key player.

Authors:  Riccardo Di Fiore; Rosa Drago-Ferrante; Antonella D'Anneo; Giuseppa Augello; Daniela Carlisi; Anna De Blasio; Michela Giuliano; Giovanni Tesoriere; Renza Vento
Journal:  Cancer Biol Ther       Date:  2013-08-12       Impact factor: 4.742

Review 10.  Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Ageing Res Rev       Date:  2008-12-09       Impact factor: 10.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.